WALTHAM, Mass., Oct. 11 /PRNewswire-FirstCall/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO), the world leader in serving science, today
announced its plan to construct an $11 million, state-of-the-art BioCenter
for the manufacture of single-use bioprocess containers (BPCs) and related
products at the site of its existing bioprocess production business unit in
Logan, Utah.
The BioCenter investment is a response to the increasing demand for
disposable bioprocessing technology among customers in the life-sciences
research, biotechnology and pharmaceutical industries. Bioprocess
containers serve cell-culture applications as well as the production of
protein-based drugs, and are used in mixing, storage and transportation of
bioprocessing fluids and for bioreactors (used to grow cells, proteins and
other biochemically active substances). Single-use bioprocessing components
eliminate the risk of batch-to-batch cross contamination and significantly
reduce startup costs for customers.
"We are excited about the expanded capabilities that our BioCenter will
provide," said Marc N. Casper, executive vice president of Thermo Fisher
Scientific. "The market outlook for the bioprocessing industry continues to
be very bright as there are thousands of biotech products under
development. This investment will allow us to better meet the needs of our
customers as they work toward new therapies for treating disease and
improving health."
The 37,000-square-foot facility is expected to be complete by the fall
of 2008. It is the first of a three-phase construction plan that will
create a 94,000-square-foot BioCenter over the next four years, replacing
and expanding an older BPC operation in Logan. The new operation will
include an administration building, sera and liquid-media processing
facility, powdered- media facility, warehouse and the existing BPC
facility. The initial project is expected to create 75 new jobs, both in
production and management functions.
Products to be manufactured in the new facility include the Thermo
Scientific HyClone BPC line -- ranging from simple bioprocess containers,
to complex bioprocessing systems and custom-designed units for a variety of
applications. This offering includes sterile fluid-handling bags, bag
manifold systems, tank liners, chambers, biopharmaceutical tubing and other
accessories, as well as the recently introduced Thermo Scientific HyClone
Single-Use Bioreactor (S.U.B.) and Single-Use Mixer (S.U.M.).
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in
serving science, enabling our customers to make the world healthier,
cleaner and safer. With an annual revenue rate of more than $9 billion, we
employ 30,000 people and serve over 350,000 customers within pharmaceutical
and biotech companies, hospitals and clinical diagnostic labs,
universities, research institutions and government agencies, as well as
environmental and industrial process control settings. Serving customers
through two premier brands, Thermo Scientific and Fisher Scientific, we
help solve analytical challenges from routine testing to complex research
and discovery. Thermo Scientific offers customers a complete range of
high-end analytical instruments as well as laboratory equipment, software,
services, consumables and reagents to enable integrated laboratory workflow
solutions. Fisher Scientific provides a complete portfolio of laboratory
equipment, chemicals, supplies and services used in healthcare, scientific
research, safety and education. Together, we offer the most convenient
purchasing options to customers and continuously advance our technologies
to accelerate the pace of scientific discovery, enhance value for customers
and fuel growth for shareholders and employees alike. Visit
http://www.thermofisher.com.
The following constitutes a "Safe Harbor" statement under the Private
Securities Litigation Reform Act of 1995: This press release contains
forward- looking statements that involve a number of risks and
uncertainties. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements are set
forth in the company's Quarterly Report on Form 10-Q for the quarter ended
June 30, 2007, under the caption "Risk Factors," which is on file with the
Securities and Exchange Commission and available in the "Investors" section
of our Website under the heading "SEC Filings." We also may make
forward-looking statements about the benefits of the merger of Thermo
Electron and Fisher Scientific, including statements about future financial
and operating results, the new company's plans, objectives, expectations
and intentions and other statements that are not historical facts.
Important factors that could cause actual results to differ materially from
those indicated by forward-looking statements include risks and
uncertainties relating to: the risk that the businesses will not be
integrated successfully; the risk that the cost savings and any other
synergies from the transaction may not be fully realized or may take longer
to realize than expected; disruption from the transaction making it more
difficult to maintain relationships with customers, employees or suppliers;
competition and its effect on pricing, spending, third-party relationships
and revenues; the need to develop new products and adapt to significant
technological change; implementation of strategies for improving internal
growth; use and protection of intellectual property; dependence on
customers' capital spending policies and government funding policies;
realization of potential future savings from new productivity initiatives;
general worldwide economic conditions and related uncertainties; the effect
of changes in governmental regulations; the effect of exchange rate
fluctuations on international operations; the effect of laws and
regulations governing government contracts; the effect of competing with
certain of our customers and suppliers; and the effect of rapid changes in
the healthcare industry. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so, even if our estimates change and, therefore, you
should not rely on these forward-looking statements as representing our
views as of any date subsequent to today.
Media Contact:
Lori Gorski
Public Relations Manager
Thermo Fisher Scientific
(781) 622-1242
Email: lori.gorski@thermofisher.com
Investor Contact:
Ken Apicerno
Thermo Fisher Scientific
(781) 622-1111
E-mail: ken.apicerno@thermofisher.com
Web site: http://www.thermofisher.com/hyclone
SOURCE Thermo Fisher Scientific Inc.
 back to top
Related links:
http://www.thermofisher.com
http://www.prnewswire.com/comp/877850.html /
CONTACT:
Media: Lori Gorski, Public Relations Manager,
+1-781-622-1242, lori.gorski@thermofisher.com, or Investors: Ken
Apicerno, +1-781-622-1111, ken.apicerno@thermofisher.com, both of
Thermo Fisher Scientific
|
